
April 14 (Reuters) - Carmat SA ALCAR.PA:
RECRUITMENT FOR SECOND COHORT EXPECTED TO BEGIN IN H2 2025
CARMAT: RECRUITMENT OF SECOND COHORT EXPECTED TO BEGIN IN H2 2025
CARMAT RECEIVES FDA CONDITIONAL APPROVAL TO INITIATE THE SECOND COHORT OF THE EFS STUDY IN THE UNITED STATES
TO INITIATE IMPLANTS IN SECOND HALF OF 2025
EFS STUDY INVOLVES 10 PATIENTS, PRIMARY ENDPOINT IS 6-MONTH SURVIVAL
TO SEEK FDA APPROVAL FOR LATEST VERSION OF AESON